Effects of financial support on treatment of adolescents with growth hormone deficiency: a retrospective study in Japan
| Autor: | Tomonobu Hasegawa, Takahiro Higashi, Susumu Yokoya, Toshiaki Tanaka, Kunihiko Hanew, Toru Yorifuji, Junko Ito, Susumu Kanzaki, Akira Shimatsu, Takahiro Mochizuki, Tomohiro Ishii, Reiko Horikawa, Naohiro Wada, Koji Takano, Toshiro Nagai, Eri Maeda, Akira Teramoto, Toshihiro Tajima, Yusuke Tanahashi, Hiroyuki Tanaka |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
Male
medicine.medical_specialty Adolescent 030209 endocrinology & metabolism Children with special health care needs Logistic regression Growth hormone deficiency 03 medical and health sciences 0302 clinical medicine Health insurance Quality of life Japan 030225 pediatrics Medicine Financial Support Humans Child Growth Disorders Retrospective Studies Finance business.industry Human Growth Hormone Public health Health Policy lcsh:Public aspects of medicine Retrospective cohort study Bone age lcsh:RA1-1270 Odds ratio medicine.disease Confidence interval Body Height Public funding Quality of Life Female business Research Article |
| Zdroj: | BMC Health Services Research, Vol 16, Iss 1, Pp 1-8 (2016) BMC Health Services Research |
| ISSN: | 1472-6963 |
| Popis: | Background Treatment costs for children with growth hormone (GH) deficiency are subsidized by the government in Japan if the children meet clinical criteria, including height limits (boys: 156.4 cm; girls: 145.4 cm). However, several funding programs, such as a subsidy provided by local governments, can be used by those who exceed the height limits. In this study, we explored the impacts of financial support on GH treatment using this natural allocation. Methods A retrospective analysis of 696 adolescent patients (451 boys and 245 girls) who reached the height limits was conducted. Associations between financial support and continuing treatment were assessed using multiple logistic regression analyses adjusting for age, sex, height, growth velocity, bone age, and adverse effects. Results Of the 696 children in the analysis, 108 (15.5 %) were still eligible for financial support. The proportion of children who continued GH treatment was higher among those who were eligible for support than among those who were not (75.9 % vs. 52.0 %, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|